251 related articles for article (PubMed ID: 30091023)
1. Autoimmune manifestations associated with myelodysplastic syndromes.
Grignano E; Jachiet V; Fenaux P; Ades L; Fain O; Mekinian A
Ann Hematol; 2018 Nov; 97(11):2015-2023. PubMed ID: 30091023
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity and Inflammation in Myelodysplastic Syndromes.
Wolach O; Stone R
Acta Haematol; 2016; 136(2):108-17. PubMed ID: 27337745
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.
Enright H; Jacob HS; Vercellotti G; Howe R; Belzer M; Miller W
Br J Haematol; 1995 Oct; 91(2):403-8. PubMed ID: 8547082
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
Braun T; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
[TBL] [Abstract][Full Text] [Related]
5. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndrome associated with multiple autoimmune disorders.
Farmakis D; Polymeropoulos E; Polonifi A; Deftereos S; Giakoumi X; Floudas H; Grapsa A; Aessopos A
Clin Rheumatol; 2005 Aug; 24(4):428-30. PubMed ID: 15827686
[TBL] [Abstract][Full Text] [Related]
7. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
[TBL] [Abstract][Full Text] [Related]
8. [Systemic and autoimmune manifestations in myelodysplastic syndromes].
Fain O; Braun T; Stirnemann J; Fenaux P
Rev Med Interne; 2011 Sep; 32(9):552-9. PubMed ID: 20850913
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
Wesner N; Drevon L; Guedon A; Fraison JB; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Eur J Haematol; 2019 Jan; 102(1):63-69. PubMed ID: 30218579
[TBL] [Abstract][Full Text] [Related]
10. Immune Mechanisms in Myelodysplastic Syndrome.
Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes.
Fozza C
Ann Hematol; 2019 Apr; 98(4):1025-1026. PubMed ID: 30310984
[No Abstract] [Full Text] [Related]
12. Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome: A Retrospective Cohort Study.
Lee SJ; Park JK; Lee EY; Joo SH; Jung KC; Lee EB; Song YW; Yoon SS
Medicine (Baltimore); 2016 Mar; 95(13):e3091. PubMed ID: 27043672
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Saif MW; Hopkins JL; Gore SD
Leuk Lymphoma; 2002 Nov; 43(11):2083-92. PubMed ID: 12533032
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Seguier J; Gelsi-Boyer V; Ebbo M; Hamidou Z; Charbonnier A; Bernit E; Durand JM; Harlé JR; Vey N; Schleinitz N
Autoimmun Rev; 2019 Jan; 18(1):36-42. PubMed ID: 30408583
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune phenomena in patients with myelodysplastic syndromes.
Enright H; Miller W
Leuk Lymphoma; 1997 Feb; 24(5-6):483-9. PubMed ID: 9086438
[TBL] [Abstract][Full Text] [Related]
17. [Systemic diseases in myelodysplastic syndromes].
Hebbar M; Hebbar-Savéan K; Fenaux P
Rev Med Interne; 1995; 16(12):897-904. PubMed ID: 8570952
[TBL] [Abstract][Full Text] [Related]
18. The relationship between myelodysplastic syndromes and autoimmune disorders.
Zhao S; Mao H; Wang H; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):311-3. PubMed ID: 12411063
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.
Giannouli S; Voulgarelis M
Expert Rev Clin Immunol; 2014 Dec; 10(12):1679-88. PubMed ID: 25308147
[TBL] [Abstract][Full Text] [Related]
20. [Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)].
Bouali F; Berrah A; Si Ahmed-Bouali D; Harrieche F; Benhalima M; Hamladji RM; Arrada M
Rev Med Interne; 2005 Oct; 26(10):777-83. PubMed ID: 16203055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
